...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours
【24h】

Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours

机译：成年实体瘤患者化疗期间血清抗体对流感病毒疫苗的反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Higher rates of hospitalization and mortality are described in oncology patients with influenza virus infection compared to the general population. Yearly influenza vaccination is recommended for patients treated with chemotherapy. The optimal moment to administer the vaccine during a treatment cycle has not been studied extensively. Patients and methods: During the influenza season 2011-2012 we conducted a multicenter randomized controlled trial (OFLUVAC, NTR2858, no sponsoring) in the Netherlands. Patients receiving adjuvant chemotherapy for breast or colorectal cancer were randomized between early (day 5 after chemotherapy) and late (day 16 after chemotherapy) vaccination with the influenza virus vaccine (Influvac (R) 2011/2012-Vaxigrip (R) 2011/2012). Influenza virus-specific antibody titres were determined before, 3 and 12 weeks after vaccination by haemagglutination inhibition. Results: Thirty-eight breast cancer patients (early = 21; late = 17) and 18 colorectal cancer patients (early = 8; late = 10) were analyzed. In breast cancer patients overall serologic responses were adequate. A statistically significant higher response in patients who received early compared to late vaccination in the chemotherapy cycle was observed. Geometric mean titres post vaccination on day 5 versus day 16 were 69.3 versus 27.4 (H3N2), 76.4 versus 17.5 (H1N1) and 34.4 versus 26.0 (B/Brisbane), respectively. In colorectal cancer patients overall serologic responses were adequate, no significant difference was found between early and late vaccination. Geometric mean titres post vaccination on day 5 versus day 16 were 170.1 versus 192.4 (H3N2), 233.0 versus 280.8 (H1N1) and 62.6 versus 75.9 (B/Brisbane), respectively. Conclusion: Overall antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast or colorectal cancer patients is adequate. Breast cancer patients seem to mount the best antibody response when vaccinated early after a chemotherapy cycle (<= day 5). No difference was found between early and late vaccination in colorectal cancer patients
机译：背景：与普通人群相比，患有流感病毒感染的肿瘤患者的住院率和死亡率更高。建议接受化疗的患者每年接种流感疫苗。在治疗周期内给予疫苗的最佳时机尚未得到广泛研究。患者和方法：在2011-2012年流感季节，我们在荷兰进行了一项多中心随机对照试验（OFLUVAC，NTR2858，无赞助）。接受乳腺癌或大肠癌辅助化疗的患者在早期（化疗后第5天）和晚期（化疗后第16天）之间接种流感病毒疫苗（Influvac（R）2011 / 2012-Vaxigrip（R）2011/2012） 。通过血凝抑制，在疫苗接种之前，3周和12周后确定流感病毒特异性抗体滴度。结果：分析了38例乳腺癌患者（早期= 21;晚期= 17）和18例结直肠癌患者（早期= 8;晚期= 10）。在乳腺癌患者中，总体血清学反应是足够的。观察到在化疗周期中较早接种与较晚接种相比，统计学上显着更高的反应。接种后第5天与第16天的几何平均滴度分别为69.3对27.4（H3N2），76.4对17.5（H1N1）和34.4对26.0（B /布里斯班）。在大肠癌患者中，总体血清学反应足够，早期和晚期疫苗接种之间无显着差异。接种后第5天与第16天的几何平均滴度分别为170.1对192.4（H3N2），233.0对280.8（H1N1）和62.6对75.9（B /布里斯班）。结论：对于乳腺癌或大肠癌患者，化疗患者对流感病毒疫苗的总体抗体反应是足够的。当在化疗周期后（<=第5天）早期接种疫苗时，乳腺癌患者似乎具有最佳的抗体反应。大肠癌患者早期和晚期接种之间没有差异

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号